Investegate |Pixium Vision Announcements | Pixium Vision: Continuation of the business combination project between Pixium Vision et Second Sight Medical Products investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
FinancialBuzz.com’s latest
The Buzz Show: Featuring Our Corporate News Recap on “Second Sight Medical Receives FDA Approval for the Argus 2s Retinal Prosthesis System”
Second Sight Medical
(NASDAQ: EYES) Products surged just under 60% in premarket trading after the company announced the U.S. Food and Drug Administration has approved the Argus 2s Retinal Prosthesis System.
The Company expects that the redesigned set of external hardware initially for use in combination with previously implanted Argus II systems for the treatment of retinitis pigmentosa, will be adapted to be the external system for the next generation Orion Visual Cortical Prosthesis System, currently under development.
Cash position at 31 December 2020: â¬10.6 million Cash runway to end of 2021 PRIMAvera European pivotal study of Prima System initiated in Q4 2020 Paris, 19 February 2021 â 7.00 a.m. CET - Pixium Vision (FR0011950641 - PIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, announces its financial results for 2020. The 2020 financial statements were approved by Pixium Vision s Board of Directors at its meeting on 18 February 2021.
Lloyd Diamond, CEO of Pixium Vision commented We continued in 2020 to deliver on our plan of transitioning Pixium Vision from a research project to a commercially oriented company. We progressed our innovative Prima System to the last step of clinical development in Europe by initiating the PRIMAvera pivotal study and strengthened our presence in the US in anticipation of increasing clinical development in this key market. We are well positio